You are here
Strategies for Stopping TKIs Growing Clearer
In patients with chronic myeloid leukemia (CML), longer treatment duration is associated with an increase in the odds ratio for preserving a major molecular response (MMR) six months after discontinuing tyrosine kinase inhibitor (TKI) therapy, according to recent data from a large study. In contrast, the depth of molecular response was not a predictor of molecular relapse-free survival (MRFS).
In EURO-SKI Study (European Stop Tyrosine Kinase Inhibitor Study), one of several CML treatment-stopping studies from which new data were presented at the 2016 annual meeting of the American Society of Hematology (ASH), the odds ratio for MRFS was 1.16. Thus, “...one additional year of treatment increases the odds to stay in MMR at six months by 16%...” reported François-Xavier Mahon, MD, PhD, Professor of Haematology and Oncology, Bergonié Cancer Institute, University of Bordeaux, France.